$OLMA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Olema Pharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Olema Pharmaceuticals, Inc.. Get notifications about new insider transactions in Olema Pharmaceuticals, Inc. for free.
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 10 2021 | OLMA | Olema Pharmaceutic ... | Hrustanovic Gorjan | Option Exercise | A | 27.66 | 21,520 | 595,243 | 21,520 | ||
Jun 10 2021 | OLMA | Olema Pharmaceutic ... | Larson Yi | Option Exercise | A | 27.66 | 21,520 | 595,243 | 21,520 | ||
May 26 2021 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | J | 0.00 | 99,556 | 0 | 99,556 | 0 to 99.6 K |
Apr 06 2021 | OLMA | Olema Pharmaceutic ... | Larson Yi | Option Exercise | A | 34.80 | 3,773 | 131,300 | 3,773 | ||
Apr 06 2021 | OLMA | Olema Pharmaceutic ... | Larson Yi | Option Exercise | A | 34.80 | 21,520 | 748,896 | 21,520 | ||
Mar 16 2021 | OLMA | Olema Pharmaceutic ... | Horn Kinney | Chief Business Offi ... | Option Exercise | A | 45.63 | 40,000 | 1,825,200 | 40,000 | |
Mar 16 2021 | OLMA | Olema Pharmaceutic ... | Bohen Sean | President and CEO | Option Exercise | A | 45.63 | 75,000 | 3,422,250 | 75,000 | |
Nov 24 2020 | OLMA | Olema Pharmaceutic ... | Wellington Biomedical Innovati ... | 10% Owner | Option Exercise | C | 0.00 | 451,986 | 0 | 0 | |
Nov 24 2020 | OLMA | Olema Pharmaceutic ... | Wellington Biomedical Innovati ... | 10% Owner | Option Exercise | C | 0.00 | 1,273,420 | 0 | 0 | |
Nov 24 2020 | OLMA | Olema Pharmaceutic ... | Wellington Biomedical Innovati ... | 10% Owner | Buy | C | 0.00 | 451,986 | 0 | 1,725,406 | 1.3 M to 1.7 M (+35.49 %) |
Nov 24 2020 | OLMA | Olema Pharmaceutic ... | Wellington Biomedical Innovati ... | 10% Owner | Buy | C | 0.00 | 1,273,420 | 0 | 1,273,420 | 0 to 1.3 M |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Cormorant Asset Management, LP | Option Exercise | C | 0.00 | 723,177 | 0 | 0 | ||
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Cormorant Asset Management, LP | Option Exercise | C | 0.00 | 2,122,367 | 0 | 0 | ||
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Cormorant Asset Management, LP | Buy | P | 19.00 | 425,000 | 8,075,000 | 3,270,544 | 2.8 M to 3.3 M (+14.94 %) | |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Cormorant Asset Management, LP | Buy | C | 0.00 | 2,845,544 | 0 | 2,845,544 | 0 to 2.8 M | |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | RAPPAPORT ANDREW | Director | Option Exercise | C | 0.00 | 129,833 | 0 | 0 | |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | RAPPAPORT ANDREW | Director | Option Exercise | C | 0.00 | 318,723 | 0 | 0 | |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | RAPPAPORT ANDREW | Director | Buy | C | 0.00 | 129,833 | 0 | 481,014 | 351.2 K to 481 K (+36.97 %) |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | RAPPAPORT ANDREW | Director | Buy | C | 0.00 | 318,723 | 0 | 351,181 | 32.5 K to 351.2 K (+981.96 %) |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Myles David C. | Chief Development O ... | Option Exercise | C | 0.00 | 154,846 | 0 | 0 | |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Myles David C. | Chief Development O ... | Option Exercise | C | 0.00 | 12,831 | 0 | 0 | |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Myles David C. | Chief Development O ... | Buy | C | 0.00 | 154,846 | 0 | 154,846 | 0 to 154.8 K |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Myles David C. | Chief Development O ... | Buy | C | 0.00 | 12,831 | 0 | 12,831 | 0 to 12.8 K |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | MCCORMICK FRANK | Director | Option Exercise | C | 0.00 | 66,326 | 0 | 0 | |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | MCCORMICK FRANK | Director | Option Exercise | C | 0.00 | 152,891 | 0 | 0 | |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | MCCORMICK FRANK | Director | Buy | C | 0.00 | 66,326 | 0 | 84,260 | 17.9 K to 84.3 K (+369.83 %) |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | MCCORMICK FRANK | Director | Buy | C | 0.00 | 152,891 | 0 | 191,113 | 38.2 K to 191.1 K (+400.01 %) |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Kushner Peter J. | Chief Scientific Of ... | Option Exercise | C | 0.00 | 130,159 | 0 | 0 | |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Kushner Peter J. | Chief Scientific Of ... | Option Exercise | C | 0.00 | 228,761 | 0 | 0 | |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Kushner Peter J. | Chief Scientific Of ... | Buy | C | 0.00 | 130,159 | 0 | 1,431,672 | 1.3 M to 1.4 M (+10.00 %) |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Kushner Peter J. | Chief Scientific Of ... | Buy | C | 0.00 | 228,761 | 0 | 1,301,513 | 1.1 M to 1.3 M (+21.32 %) |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Harmon Cyrus | Chief Technology Of ... | Option Exercise | C | 0.00 | 122,028 | 0 | 0 | |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Harmon Cyrus | Chief Technology Of ... | Option Exercise | C | 0.00 | 71,374 | 0 | 0 | |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Harmon Cyrus | Chief Technology Of ... | Buy | C | 0.00 | 122,028 | 0 | 122,028 | 0 to 122 K |
Nov 23 2020 | OLMA | Olema Pharmaceutic ... | Harmon Cyrus | Chief Technology Of ... | Buy | C | 0.00 | 71,374 | 0 | 1,111,546 | 1 M to 1.1 M (+6.86 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 73,399 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 522,403 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 760,155 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 101,784 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 673,281 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 889,186 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 185,908 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 881,156 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 1,129,404 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | A | 19.00 | 21,520 | 408,880 | 21,520 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | A | 19.00 | 21,520 | 408,880 | 21,520 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | A | 19.00 | 21,520 | 408,880 | 21,520 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | P | 19.00 | 74,991 | 1,424,829 | 436,082 | 361.1 K to 436.1 K (+20.77 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 73,399 | 0 | 361,091 | 287.7 K to 361.1 K (+25.51 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 101,784 | 0 | 287,692 | 185.9 K to 287.7 K (+54.75 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 185,908 | 0 | 185,908 | 0 to 185.9 K |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | P | 19.00 | 446,425 | 8,482,075 | 2,523,265 | 2.1 M to 2.5 M (+21.50 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 73,399 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 522,403 | 0 | 2,076,840 | 1.6 M to 2.1 M (+33.61 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 522,403 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 673,281 | 0 | 1,554,437 | 881.2 K to 1.6 M (+76.41 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 760,155 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 881,156 | 0 | 881,156 | 0 to 881.2 K |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 101,784 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | P | 19.00 | 613,918 | 11,664,442 | 3,392,663 | 2.8 M to 3.4 M (+22.09 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 673,281 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 760,155 | 0 | 2,778,745 | 2 M to 2.8 M (+37.66 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 889,186 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 889,186 | 0 | 2,018,590 | 1.1 M to 2 M (+78.73 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 185,908 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 1,129,404 | 0 | 1,129,404 | 0 to 1.1 M |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 881,156 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 1,129,404 | 0 | 0 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | A | 19.00 | 21,520 | 408,880 | 21,520 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | A | 19.00 | 21,520 | 408,880 | 21,520 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | A | 19.00 | 21,520 | 408,880 | 21,520 | |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | P | 19.00 | 74,991 | 1,424,829 | 436,082 | 361.1 K to 436.1 K (+20.77 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 73,399 | 0 | 361,091 | 287.7 K to 361.1 K (+25.51 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 101,784 | 0 | 287,692 | 185.9 K to 287.7 K (+54.75 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 185,908 | 0 | 185,908 | 0 to 185.9 K |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | P | 19.00 | 446,425 | 8,482,075 | 2,523,265 | 2.1 M to 2.5 M (+21.50 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 522,403 | 0 | 2,076,840 | 1.6 M to 2.1 M (+33.61 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 673,281 | 0 | 1,554,437 | 881.2 K to 1.6 M (+76.41 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 881,156 | 0 | 881,156 | 0 to 881.2 K |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | P | 19.00 | 613,918 | 11,664,442 | 3,392,663 | 2.8 M to 3.4 M (+22.09 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 760,155 | 0 | 2,778,745 | 2 M to 2.8 M (+37.66 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 889,186 | 0 | 2,018,590 | 1.1 M to 2 M (+78.73 %) |
Nov 20 2020 | OLMA | Olema Pharmaceutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 1,129,404 | 0 | 1,129,404 | 0 to 1.1 M |
Nov 19 2020 | OLMA | Olema Pharmaceutic ... | Graham G. Walmsley | Director | Option Exercise | A | 19.00 | 21,520 | 408,880 | 21,520 | |
Nov 19 2020 | OLMA | Olema Pharmaceutic ... | Graham G. Walmsley | Director | Option Exercise | A | 19.00 | 21,520 | 408,880 | 21,520 | |
Nov 19 2020 | OLMA | Olema Pharmaceutic ... | Graham G. Walmsley | Director | Option Exercise | A | 19.00 | 21,520 | 408,880 | 21,520 | |
Nov 19 2020 | OLMA | Olema Pharmaceutic ... | Graham G. Walmsley | Director | Option Exercise | P | 0.00 | 1,183,114 | 0 | 1,183,114 | |
Nov 19 2020 | OLMA | Olema Pharmaceutic ... | Graham G. Walmsley | Director | Option Exercise | P | 0.00 | 339,578 | 0 | 339,578 | |
Nov 19 2020 | OLMA | Olema Pharmaceutic ... | RAPPAPORT ANDREW | Director | Option Exercise | A | 19.00 | 21,520 | 408,880 | 21,520 | |
Nov 19 2020 | OLMA | Olema Pharmaceutic ... | RAPPAPORT ANDREW | Director | Option Exercise | A | 4.82 | 56,964 | 274,794 | 56,964 | |
Nov 19 2020 | OLMA | Olema Pharmaceutic ... | Myles David C. | Chief Development O ... | Option Exercise | A | 19.00 | 179,340 | 3,407,460 | 179,340 | |
Nov 19 2020 | OLMA | Olema Pharmaceutic ... | Myles David C. | Chief Development O ... | Grant | A | 0.00 | 143,472 | 0 | 591,821 | 448.3 K to 591.8 K (+32.00 %) |
Page: 1